Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Blueprint Medicines Corp (NASDAQ: BPMC) closed at $86.00 down -3.73% from its previous closing price of $89.33. In other words, the price has decreased by -$3.73 from its previous closing price. On the day, 0.75 million shares were traded. BPMC stock price reached its highest trading level at $89.64 during the session, while it also had its lowest trading level at $85.79.
Ratios:
For a deeper understanding of Blueprint Medicines Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.71. In the meantime, Its Debt-to-Equity ratio is 2.31 whereas as Long-Term Debt/Eq ratio is at 1.95.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on May 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $140.
On May 06, 2024, Leerink Partners Upgraded its rating to Market Perform which previously was Underperform and also upped its target price recommendation from $50 to $97.
Oppenheimer Upgraded its Perform to Outperform on October 27, 2023, while the target price for the stock was maintained at $85.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 03 ’24 when Namouni Fouad sold 3,633 shares for $89.32 per share. The transaction valued at 324,500 led to the insider holds 69,070 shares of the business.
Albers Jeffrey W. sold 19,702 shares of BPMC for $1,685,891 on Sep 09 ’24. The Director now owns 157,557 shares after completing the transaction at $85.57 per share. On Sep 09 ’24, another insider, Albers Jeffrey W., who serves as the Director of the company, bought 19,702 shares for $85.57 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5447712768 and an Enterprise Value of 5424457216. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.02 while its Price-to-Book (P/B) ratio in mrq is 16.96. Its current Enterprise Value per Revenue stands at 14.952 whereas that against EBITDA is -15.809.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is -5.04%, while the 200-Day Moving Average is calculated to be -9.26%.
Shares Statistics:
For the past three months, BPMC has traded an average of 657.79K shares per day and 458150 over the past ten days. A total of 63.35M shares are outstanding, with a floating share count of 62.20M. Insiders hold about 1.82% of the company’s shares, while institutions hold 105.40% stake in the company. Shares short for BPMC as of 1727654400 were 3529107 with a Short Ratio of 5.37, compared to 1724976000 on 3962911. Therefore, it implies a Short% of Shares Outstanding of 3529107 and a Short% of Float of 6.280000500000001.
